An interarterial shunt (IAS) device that showed promise in improving heart failure (HF) in pilot studies did not meet the primary efficacy endpoint in a pivotal trial. The trial showed potential harm among patients with preserved left ventricular ejection fraction (LVEF) greater than 40%. Results indicated that the IAS device was beneficial for patients with reduced LVEF but harmful for those with preserved LVEF. There was no significant difference in overall composite endpoints between the groups, but HF hospitalizations and deaths were significantly higher among patients with preserved LVEF who received the IAS device. Further studies are needed to confirm these findings.
Source link
No Net HF Benefit for Interarterial Shunt Device
